Novartis steps down completely from Vaccines’ Business

31/10/2014 - 2 minutes

Novartis divests its influenza vaccines business to CSL Limited, an Australian company, for an agreed price of 219 million euros, completing the last deal with GSK a few months ago. This is a strategic move of Novartis; they plan to focus on the pharmaceutical business, ophthalmology (Alcon) and generics (Sandoz). 

Last year, influenza vaccine business reached a turnover of 1 billion euro. CSL was chosen because of their 40 years of experience in this business and will lead CSL to become the world’s second largest in the sector, with a market estimated to 3 billion euros. This transaction requires regulatory approvals and is expected to close in the second half of 2015.

Moreover, in April, Novartis signed a definitive agreement with GSK to exchange certain assets, building global leadership in key segments and focusing on its portfolio. Under this agreement, Novartis wanted to strengthen the company’s innovative pharmaceuticals business by acquiring GSK oncology products, and would divest Novartis Vaccines (excluding influenza) to GSK. Both companies also jointed forces to create a joint venture,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member